Avalo Therapeutics Sets Q2 2026 for AVTX-009 Trial Results; Confirms Funding Runway

Avalo Therapeutics (AVTX) has announced that it expects the Phase IIb LOTUS study results for its drug candidate AVTX-009 in the second quarter of 2026. The drug is designed to target IL-1 beta, which is identified as a primary upstream driver of hidradenitis suppurativa (HS). Management confirmed that patient enrollment for the study has been successfully completed, marking a significant operational milestone for the clinical program. Crucially, the company stated it maintains a sufficient cash balance to fund operations through the anticipated data readout milestone. This update provides investors with a clear clinical timeline and reduces immediate concerns regarding liquidity and research funding. While the long-term nature of the trial remains a factor, the operational progress strengthens the company's position within the biotech sector.